Ludger Johannes (PhD) is Research Director (DRE) at INSERM. He is a member of Studienstiftung des Deutschen Volkes (German organization of the academically gifted), Boehringer Ingelheim Fonds, European Molecular Biology Organization (EMBO), and German Academy of Science — Leopoldina. At Institut Curie, he has been heading since 2001 the Traffic, Signaling, and Delivery Team, and since 2014 the Cellular and Chemical Biology unit (U1143 INSERM — UMR3666 CNRS). His research aims at establishing fundamental concepts of endocytosis and intracellular trafficking with two major contributions in this context: The discovery of the membrane trafficking interface between early endosomes and the Golgi apparatus and the demonstration that dynamic lectin-induced glycolipid reorganization acts as a driving force for endocytic pit construction in clathrin-independent endocytosis. The studies of the Johannes team have been published in highly visible journals (Cell, Nature, Nature Cell Biology, and Nature Nanotechnology…). Between 2014 and 2020, he held an ERC advanced grant. He also aims at exploiting the discoveries of his team in fundamental membrane biology research for the development of innovative cancer therapy strategies, notably by using the B-subunit of Shiga toxin (STxB) as a "pilot" for the delivery of therapeutic compounds to precise intracellular locations of dendritic cells for immunotherapy, and to tumors for targeted therapy.
Ludger Johannes (PhD) is Research Director (DRE) at INSERM. He is a member of Studienstiftung des Deutschen Volkes (German organization of the academically gifted), Boehringer Ingelheim Fonds, European Molecular Biology Organization (EMBO), and German Academy of Science — Leopoldina. At Institut Curie, he has been heading since 2001 the Traffic, Signaling, and Delivery Team, and since 2014 the Cellular and Chemical Biology unit (U1143 INSERM — UMR3666 CNRS). His research aims at establishing fundamental concepts of endocytosis and intracellular trafficking with two major contributions in this context: The discovery of the membrane trafficking interface between early endosomes and the Golgi apparatus and the demonstration that dynamic lectin-induced glycolipid reorganization acts as a driving force for endocytic pit construction in clathrin-independent endocytosis. The studies of the Johannes team have been published in highly visible journals (Cell, Nature, Nature Cell Biology, and Nature Nanotechnology…). Between 2014 and 2020, he held an ERC advanced grant. He also aims at exploiting the discoveries of his team in fundamental membrane biology research for the development of innovative cancer therapy strategies, notably by using the B-subunit of Shiga toxin (STxB) as a "pilot" for the delivery of therapeutic compounds to precise intracellular locations of dendritic cells for immunotherapy, and to tumors for targeted therapy.